{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:36:15Z","timestamp":1784824575947,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222627\/Z\/21\/Z"],"award-info":[{"award-number":["222627\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["NIHR302549"],"award-info":[{"award-number":["NIHR302549"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018262","name":"Intercept Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018262","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.diabres.2024.111820","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T19:42:07Z","timestamp":1723578127000},"page":"111820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1724-498X","authenticated-orcid":false,"given":"Santo","family":"Colosimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1198-6093","authenticated-orcid":false,"given":"Hamish","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios A.","family":"Koutoukidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Marjot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry D.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Harman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinelopi","family":"Manousou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Forlano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4888-8670","authenticated-orcid":false,"given":"Richard","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-814X","authenticated-orcid":false,"given":"David A.","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Alazawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8680-619X","authenticated-orcid":false,"given":"Jeremy F.","family":"Cobbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy W.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.diabres.2024.111820_b0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","article-title":"The global burden of metabolic disease: Data from 2000 to 2019","volume":"35","author":"Chew","year":"2023","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.diabres.2024.111820_b0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2024.111820_b0015","article-title":"Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies","author":"Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2024.111820_b0020","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.diabres.2024.111820_b0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hep.32594","article-title":"Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD","volume":"77","author":"Gidener","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111820_b0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fphar.2016.00159","article-title":"Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy?","volume":"7","author":"Chin","year":"2016","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.diabres.2024.111820_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102261","article-title":"Retrospective analysis (2009\u20132017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India","volume":"15","author":"Kamalraj","year":"2021","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"10.1016\/j.diabres.2024.111820_b0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clinre.2018.08.007","article-title":"Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes","volume":"43","author":"Yu","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"10.1016\/j.diabres.2024.111820_b0045","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2024.111820_b0050","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111820_b0055","article-title":"Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent","author":"Colosimo","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10019","key":"10.1016\/j.diabres.2024.111820_b0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.diabres.2024.111820_b0065","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.diabres.2024.111820_b0070","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.diabres.2024.111820_b0075","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2024.111820_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"issue":"7","key":"10.1016\/j.diabres.2024.111820_b0085","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2337\/db16-0236","article-title":"Fasting plasma insulin concentrations are associated with changes in hepatic fatty acid synthesis and partitioning prior to changes in liver fat content in healthy adults","volume":"65","author":"Pramfalk","year":"2016","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.diabres.2024.111820_b0090","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/oby.22821","article-title":"High glucose-aggravated hepatic insulin resistance: role of the NLRP3 inflammasome in Kupffer cells","volume":"28","author":"Zheng","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1016\/j.diabres.2024.111820_b0095","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"9972","key":"10.1016\/j.diabres.2024.111820_b0100","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.diabres.2024.111820_b0105","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/apt.15710","article-title":"Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome","volume":"51","author":"Moolla","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.diabres.2024.111820_b0110","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41401-021-00832-z","article-title":"NASH: regulatory considerations for clinical drug development and U.S. FDA approval","volume":"43","author":"Harvey","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"10.1016\/j.diabres.2024.111820_b0115","doi-asserted-by":"crossref","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","article-title":"Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease","volume":"117","author":"Vieira Barbosa","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.diabres.2024.111820_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2024.111820_b0125","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000351","article-title":"Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes","author":"Pennisi","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.diabres.2024.111820_b0130","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.cgh.2022.03.044","article-title":"Development and validation of a score for fibrotic nonalcoholic steatohepatitis","volume":"21","author":"Tavaglione","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2024.111820_b0135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2024.111820_b0140","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.diabres.2024.111820_b0145","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/liv.14799","article-title":"Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis","volume":"41","author":"Colosimo","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.diabres.2024.111820_b0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jgh3.12274","article-title":"Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes","volume":"4","author":"Marjot","year":"2020","journal-title":"JGH Open"},{"issue":"5","key":"10.1016\/j.diabres.2024.111820_b0155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.diabres.2024.111820_b0160","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2024.111820_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2024.111820_b0170","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.14025","article-title":"Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease","author":"Tamaki","year":"2024","journal-title":"Hepatol Res"},{"key":"10.1016\/j.diabres.2024.111820_b0175","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388\u2013402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"issue":"8","key":"10.1016\/j.diabres.2024.111820_b0180","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2468-1253(22)00061-9","article-title":"Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group","volume":"7","author":"McPherson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724007307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724007307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:39:09Z","timestamp":1762259949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724007307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":36,"alternative-id":["S0168822724007307"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111820","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111820"}}